Oxidative stress in ‘flashing’ mode to preserve muscle

The integration of an in silico validation phase (Phase 1) with clear GO/NO-GO criteria is judged to be excellent, as it permits the testing of physical and biological plausibility before commitment to costly experiments. The use of LHS sampling to test the robustness of predictions against parameter uncertainty is considered exemplary.

The hypothesis is grounded in a well-established mechanistic framework (AMPK-SIRT1-PGC-1α, FoxO3a, Nrf2) and is linked in a plausible manner to a novel experimental platform (OMIS). The proposition that distinct temporal profiles of oxidative stress (intermittent versus sustained) may direct signalling toward mitochondrial biogenesis or atrophy constitutes a strong, testable prediction that moves beyond classical static models.

The use of an open-hardware, millifluidic platform to deliver a spatiotemporal gradient of H₂O₂ represents a technically original approach that could, in principle, permit the dissection of non-monotonic responses frequently overlooked in static models.

A clearly identified niche market is identified: pharmaceutical R&D in muscle atrophy (cachexia, sarcopenia, bed rest) and redox toxicology. CROs (e.g., Charles River, Evotec) and biotechs (e.g., Rejuvenate Bio, MyoKardia) would pay for a predictive 3D model that reduces reliance on animal testing (cost ~€200k/rodent study).

A strong, falsifiable mechanistic hypothesis is presented, accompanied by a clear experimental design—a feature highly valued by ANR/ERC reviewers.